IP Library › Granted Patent US 12,286,477

Granted Patent B2

US 12,286,477 · App. 17/820,805 · Granted Apr 29, 2025

Anti-TCR antibody molecules and uses thereof

Inventors: Seng-Lai Tan (Sudbury, MA); Brian Edward Vash (Cambridge, MA); Jonathan Hsu (Waltham, MA); Dilini Charmain Gunasekera (Cambridge, MA); Sangeetha Sagar Palakurthi (East Walpole, MA); Andreas Loew (Boston, MA)

Assignee: MARENGO THERAPEUTICS, INC.

C07K16/2809 A61K35/17 A61K40/10 A61K40/11 A61K40/4211 A61K40/4215 A61P35/00 C07K16/2803 C07K16/283 C07K16/2878 C12N5/0634 A61K2039/505 A61K2239/31 A61K2239/38 C07K2317/24 C07K2317/31 C07K2317/55 C07K2317/622 C07K2317/92

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,286,477
App. No.: 17/820,805
Granted: Apr 29, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.

Claims (215)

1. A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a multispecific molecule,

wherein the multispecific molecule comprises a first domain that binds to a first target molecule and a second domain that binds to a second target molecule;

wherein the multispecific molecule is a T cell receptor (TCR) agonist;

wherein the second domain comprises a cytokine molecule;

wherein the first domain binds to a T cell receptor beta variable region (TCRβV) of a TCRβ chain expressed by a T cell of the subject;

wherein the TCRβV is TCRβV6, and the first domain comprises a heavy chain variable region (VH) comprising a heavy chain complementarity determining region 1 (HC CDR1), a heavy chain complementarity determining region 2 (HC CDR2), and a heavy chain complementarity determining region 3 (HC CDR3), and a light chain variable region (VL) comprising a light chain complementarity determining region 1 (LC CDR1), a light chain complementarity determining region 2 (LC CDR2), and a light chain complementarity determining region 3 (LC CDR3), wherein:

(a) the HC CDR1, the HC CDR2, the HC CDR3, the LC CDR1, the LC CDR2, and the LC CDR3 comprise the sequences of:

(i) SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 51, SEQ ID NO: 52, and SEQ ID NO: 53, respectively;

(ii) SEQ ID NO:48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 54, SEQ ID NO: 55, and SEQ ID NO: 56, respectively; or

(iii) SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively;

(b) the HC CDR1, the HC CDR2, and the HC CDR3; and the LC CDR1, the LC CDR2, and the LC CDR3 comprise the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence; and the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence of:

(i) SEQ ID NO: 82 and SEQ ID NO: 81, respectively;

(ii) SEQ ID NO: 85 and SEQ ID NO: 84, respectively;

(iii) SEQ ID NO: 88 and SEQ ID NO: 87, respectively;

(iv) SEQ ID NO: 91 and SEQ ID NO: 90, respectively;

(v) SEQ ID NO: 94 and SEQ ID NO: 93, respectively;

(vi) SEQ ID NO: 97 and SEQ ID NO: 96, respectively;

(vii) SEQ ID NO: 100 and SEQ ID NO: 99, respectively;

(viii) SEQ ID NO: 103 and SEQ ID NO: 102, respectively;

(ix) SEQ ID NO: 106 and SEQ ID NO: 105, respectively;

(x) SEQ ID NO: 109 and SEQ ID NO: 108, respectively;

(xi) SEQ ID NO: 112 and SEQ ID NO: 111, respectively;

(xii) SEQ ID NO: 115 and SEQ ID NO: 114, respectively;

(xiii) SEQ ID NO: 118 and SEQ ID NO: 117, respectively;

(xiv) SEQ ID NO: 121 and SEQ ID NO: 120, respectively;

(xv) SEQ ID NO: 124 and SEQ ID NO: 123, respectively;

(xvi) SEQ ID NO: 127 and SEQ ID NO: 126, respectively;

(xvii) SEQ ID NO: 130 and SEQ ID NO: 129, respectively;

(xviii) SEQ ID NO: 133 and SEQ ID NO: 132, respectively;

(xix) SEQ ID NO: 136 and SEQ ID NO: 135, respectively;

(xx) SEQ ID NO: 139 and SEQ ID NO: 138, respectively;

(xxi) SEQ ID NO: 142 and SEQ ID NO: 141, respectively;

(xxii) SEQ ID NO: 145 and SEQ ID NO: 144, respectively;

(xxiii) SEQ ID NO: 148 and SEQ ID NO: 147, respectively;

(xxiv) SEQ ID NO: 151 and SEQ ID NO: 150, respectively;

(xxv) SEQ ID NO: 155 and SEQ ID NO: 154, respectively;

(xxvi) SEQ ID NO: 158 and SEQ ID NO: 157, respectively;

(xxvii) SEQ ID NO: 161 and SEQ ID NO: 160, respectively;

(xxviii) SEQ ID NO: 164 and SEQ ID NO: 163, respectively;

(xxix) SEQ ID NO: 167 and SEQ ID NO: 166, respectively;

(xxx) SEQ ID NO: 170 and SEQ ID NO: 169, respectively;

(xxxi) SEQ ID NO: 173 and SEQ ID NO: 172, respectively;

(xxxii) SEQ ID NO: 176 and SEQ ID NO: 175, respectively;

(xxxiii) SEQ ID NO: 179 and SEQ ID NO: 178, respectively;

(xxxiv) SEQ ID NO: 182 and SEQ ID NO: 181, respectively;

(xxxv) SEQ ID NO: 185 and SEQ ID NO: 184, respectively;

(xxxvi) SEQ ID NO: 188 and SEQ ID NO: 187, respectively;

(xxxvii) SEQ ID NO: 191 and SEQ ID NO: 190, respectively;

(xxxviii) SEQ ID NO: 194 and SEQ ID NO: 193, respectively;

(xxxix) SEQ ID NO: 197 and SEQ ID NO: 196, respectively;

(xl) SEQ ID NO: 200 and SEQ ID NO: 199, respectively;

(xli) SEQ ID NO: 203 and SEQ ID NO: 202, respectively; or

(xlii) SEQ ID NO: 205 and SEQ ID NO: 204, respectively,

wherein the HC CDR 1 sequence, the HC CDR2 sequence, the HC CDR3 sequence, the LC CDR1 sequence, the LC CDR2 sequence, and the LC CDR3 sequence are determined by the Kabat numbering scheme, the Chothia numbering scheme, or ImMunoGeneTics (IMGT); or

(c) the HC CDR1, the HC CDR2, and the HC CDR3 comprises the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence of SEQ ID NO: 207, SEQ ID NO: 209, SEQ ID NO: 211, SEQ ID NO: 213, SEQ ID NO: 215, SEQ ID NO: 217, SEQ ID NO: 219, SEQ ID NO: 221, SEQ ID NO: 223, or SEQ ID NO: 225; and the LC CDR1, the LC CDR2, and the LC CDR3 comprise the sequences of SEQ ID NO: 51, SEQ ID NO: 52, and SEQ ID NO: 53, respectively, the sequences of SEQ ID NO: 54, SEQ ID NO: 55, and SEQ ID NO: 56, respectively, or the sequences of SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8, respectively,

wherein the HC CDR1 sequence, the HC CDR2 sequence, and the HC CDR3 sequence are determined by the Kabat numbering scheme, the Chothia numbering scheme, or ImMunoGeneTics (IMGT);

wherein the first domain comprises a full antibody or an antigen binding domain, wherein the antigen binding domain is selected from the group consisting of a Fab, a F(ab′) 2 , and a single chain Fv (scFv);

wherein the first domain does not bind to any complementarity determining regions of the TCRβ chain and does not bind to an interface of complex of the TCRβ chain and a TCRα chain; and

wherein the multispecific molecule is not immobilized to a solid-phase.

2. The method of claim 1 , wherein the method selectively expands T cells of the subject that express the TCR comprising the TCRβV.

3. The method of claim 1 , wherein

the VH and the VL comprise a sequence having at least 90% sequence identity to the sequence of:

(i) SEQ ID NO: 1 and SEQ ID NO: 2, respectively;

(ii) SEQ ID NO: 9 and SEQ ID NO: 10, respectively;

(iii) SEQ ID NO: 9 and SEQ ID NO: 11, respectively;

(iv) SEQ ID NO: 82 and SEQ ID NO: 81, respectively;

(v) SEQ ID NO: 85 and SEQ ID NO: 84, respectively;

(vi) SEQ ID NO: 88 and SEQ ID NO: 87, respectively;

(vii) SEQ ID NO: 91 and SEQ ID NO: 90, respectively;

(viii) SEQ ID NO: 94 and SEQ ID NO: 93, respectively;

(ix) SEQ ID NO: 97 and SEQ ID NO: 96, respectively;

(x) SEQ ID NO: 100 and SEQ ID NO: 99, respectively;

(xi) SEQ ID NO: 103 and SEQ ID NO: 102, respectively;

(xii) SEQ ID NO: 106 and SEQ ID NO: 105, respectively;

(xiii) SEQ ID NO: 109 and SEQ ID NO: 108, respectively;

(xiv) SEQ ID NO: 112 and SEQ ID NO: 111, respectively;

(xv) SEQ ID NO: 115 and SEQ ID NO: 114, respectively;

(xvi) SEQ ID NO: 118 and SEQ ID NO: 117, respectively;

(xvii) SEQ ID NO: 121 and SEQ ID NO: 120, respectively;

(xviii) SEQ ID NO: 124 and SEQ ID NO: 123, respectively;

(xix) SEQ ID NO: 127 and SEQ ID NO: 126, respectively;

(xx) SEQ ID NO: 130 and SEQ ID NO: 129, respectively;

(xxi) SEQ ID NO: 133 and SEQ ID NO: 132, respectively;

(xxii) SEQ ID NO: 136 and SEQ ID NO: 135, respectively;

(xxiii) SEQ ID NO: 139 and SEQ ID NO: 138, respectively;

(xxiv) SEQ ID NO: 142 and SEQ ID NO: 141, respectively;

(xxv) SEQ ID NO: 145 and SEQ ID NO: 144, respectively;

(xxvi) SEQ ID NO: 148 and SEQ ID NO: 147, respectively;

(xxvii) SEQ ID NO: 151 and SEQ ID NO: 150, respectively;

(xxviii) SEQ ID NO: 155 and SEQ ID NO: 154, respectively;

(xxix) SEQ ID NO: 158 and SEQ ID NO: 157, respectively;

(xxx) SEQ ID NO: 161 and SEQ ID NO: 160, respectively;

(xxxi) SEQ ID NO: 164 and SEQ ID NO: 163, respectively;

(xxxii) SEQ ID NO: 167 and SEQ ID NO: 166, respectively;

(xxxiii) SEQ ID NO: 170 and SEQ ID NO: 169, respectively;

(xxxiv) SEQ ID NO: 173 and SEQ ID NO: 172, respectively;

(xxxv) SEQ ID NO: 176 and SEQ ID NO: 175, respectively;

(xxxvi) SEQ ID NO: 179 and SEQ ID NO: 178, respectively;

(xxxvii) SEQ ID NO: 182 and SEQ ID NO: 181, respectively;

(xxxviii) SEQ ID NO: 185 and SEQ ID NO: 184, respectively;

(xxxix) SEQ ID NO: 188 and SEQ ID NO: 187, respectively;

(xl) SEQ ID NO: 191 and SEQ ID NO: 190, respectively;

(xli) SEQ ID NO: 194 and SEQ ID NO: 193, respectively;

(xlii) SEQ ID NO: 197 and SEQ ID NO: 196, respectively;

(xliii) SEQ ID NO: 200 and SEQ ID NO: 199, respectively;

(xliv) SEQ ID NO: 203 and SEQ ID NO: 202, respectively;

(xlv) SEQ ID NO: 205 and amino acids 140-246 of SEQ ID NO: 204, respectively;

(xlvi) SEQ ID NO: 207 and SEQ ID NO: 10, respectively;

(xlvii) SEQ ID NO: 209 and SEQ ID NO: 10, respectively;

(xlviii) SEQ ID NO: 211 and SEQ ID NO: 10, respectively;

(xlix) SEQ ID NO: 213 and SEQ ID NO: 10, respectively;

(l) SEQ ID NO: 215 and SEQ ID NO: 10, respectively;

(li) SEQ ID NO: 217 and SEQ ID NO: 10, respectively;

(lii) SEQ ID NO: 219 and SEQ ID NO: 10, respectively;

(lii) SEQ ID NO: 221 and SEQ ID NO: 10, respectively;

(liv) SEQ ID NO: 223 and SEQ ID NO: 10, respectively; or

(lv) SEQ ID NO: 225 and SEQ ID NO: 10, respectively.

4. The method of claim 1 , wherein the multispecific molecule comprises at least two non-contiguous polypeptide chains,

wherein a first polypeptide chain of the at least two non-contiguous polypeptide chains comprises a first member of a dimerization module, and a second polypeptide chain of the at least two non-contiguous polypeptide chains comprises a second member of the dimerization module, and

wherein the first polypeptide chain and the second polypeptide chain form a complex via the first member of the dimerization module and the second member of the dimerization module.

5. The method of claim 4 , wherein the first polypeptide chain comprises the first domain and the second polypeptide chain comprises the second domain, and wherein:

(i) the first polypeptide chain comprises the first domain linked to the first member of the dimerization module, and the second polypeptide chain comprises the second domain linked to the second member of the dimerization module;

(ii) the first polypeptide chain comprises a first portion of the first domain linked to the first member of the dimerization module, and the second polypeptide chain comprises a first portion of the second domain linked to the second member of the dimerization module; wherein the at least two non-contiguous polypeptide chains comprise a third polypeptide chain comprising a second portion of the first domain and a fourth polypeptide chain comprising a second portion of the second domain;

(iii) the first polypeptide chain comprises a first portion of the first domain linked to the first member of the dimerization module, and the second polypeptide chain comprises the second domain linked to the second member of the dimerization module; wherein the at least two non-contiguous polypeptide chains comprise a third polypeptide chain comprising a second portion of the first domain; or

(iv) the first polypeptide chain comprises the first domain linked to the first member of the dimerization module, and the second polypeptide chain comprises a first portion of the second domain linked to the second member of the dimerization module; wherein the at least two non-contiguous polypeptide chains comprise a third polypeptide chain comprising a second portion of the second domain.

6. The method of claim 5 , wherein the multispecific molecule further comprises a linker between the first domain and the first member of the dimerization module, a linker between the second domain and the second member of the dimerization module, a linker between the first portion of the first domain and the first member of the dimerization module, a linker between the first portion of the second domain and the second member of the dimerization module, or any combination thereof, and wherein the linker is selected from an IgG hinge, a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, and a non-helical linker.

7. The method of claim 4 , wherein the first polypeptide chain comprises (a) the first domain or a first portion of the first domain and (b) the second domain or a first portion of the second domain, and wherein the first polypeptide chain comprises:

(i) the first domain linked to the first member of the dimerization module linked to the second domain;

(ii) the first portion of the first domain linked to the first member of the dimerization module linked to the first portion of the second domain, wherein the at least two non-contiguous polypeptide chains comprise a third polypeptide chain comprising a second portion of the first domain and a fourth polypeptide chain comprising a second portion of the second domain;

(iii) the first portion of the first domain linked to the first member of the dimerization module linked to the second domain, wherein the at least two non-contiguous polypeptide chains comprise a third polypeptide chain comprising a second portion of the first domain; or

(iv) the first domain linked to the first member of the dimerization module linked to the first portion of the second domain, wherein the at least two non-contiguous polypeptide chains comprise a third polypeptide chain comprising a second portion of the second domain.

8. The method of claim 7 , wherein the multispecific molecule further comprises a linker between the first domain and the first member of the dimerization module, a linker between the first portion of the first domain and the first member of the dimerization module, a linker between the first member of the dimerization module and the second domain, a linker between the first member of the dimerization module and the first portion of the second domain, or any combination thereof, and wherein the linker is selected from an IgG hinge, a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, and a non-helical linker.

9. The method of claim 1 , wherein the multispecific molecule comprises a polypeptide sequence comprising:

(i) the first domain linked to the second domain;

(ii) a first portion of the first domain linked to a first portion of the second domain, wherein the polypeptide sequence further comprises a second portion of the first domain and a second portion of the second domain;

(iii) a first portion of the first domain linked to the second domain, wherein the polypeptide sequence further comprises a second portion of the first domain; or

(iv) the first domain linked to a first portion of the second domain, wherein the polypeptide sequence further comprises a second portion of the second domain.

10. The method of claim 9 , wherein the polypeptide sequence further comprises a linker between the first domain and the second domain, a linker between the first portion of the first domain and the first portion of the second domain, a linker between the first portion of the first domain and the second domain, a linker between the first domain and the first portion of the second domain, or any combination thereof, and wherein the linker is selected from a cleavable linker, a non-cleavable linker, a peptide linker, a flexible linker, a rigid linker, a helical linker, and a non-helical linker.

11. The method of claim 1 , wherein the multispecific molecule further comprises a third domain that comprises a domain that binds to a tumor antigen selected from the group consisting of BCMA, FcRH5, CD19, CD20, CD22, CD30, CD33, CD38, CD47, CD99, CD123, CLEC12, CD179A, SLAMF7, PDL1, gangloside 2 (GD2), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PSMA), prostate-specific antigen (PSA), carcinoembryonic antigen (CEA), Ron Kinase, c-Met, Immature laminin receptor, TAG-72, BING-4, Calcium-activated chloride channel 2, Cyclin-B1, 9D7, Ep-CAM, EphA3, Her2/neu, Telomerase, SAP-1, Survivin, NY-ESO-1/LAGE-1, PRAME, SSX-2, Melan-A/MART-1, gp100/pmel17, Tyrosinase, MC1R, b-catenin, BRCA1/2, CDK4, CML66, Fibronectin, p53, Ras, TGF-B receptor, AFP, ETA, MAGE, CA-125, BAGE, GAGE, CDC27, a actinin-4, TRP1/gp75, TRP2, gangliosides, WT1, Epidermal growth factor receptor (EGFR), MART-2, MUC1, MUC2, MUM1, MUM2, MUM3, NA88-1, NPM, OA1, OGT, RCC, RU11, RU12, SAGE, TRG, TSTA, Folate receptor alpha, L1-CAM, CAIX, gpA33, GD3, GM2, VEGFR, integrin, a carbohydrate, IGFIR, TRAILR1, TRAILR2, RANKL, FAP, TGF-beta, hyaluronic acid, collagen, tenascin C, and tenascin W.

12. The method of claim 1 , wherein the multispecific molecule further comprises a third domain that comprises an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager.

13. The method of claim 12 , wherein the third domain comprises a T cell engager that binds to a TCRβV other than the TCRβV to which the first domain binds.

14. The method of claim 12 , wherein the third domain comprises a T cell engager that does not bind to a TCRβV.

15. The method of claim 1 , wherein the multispecific molecule further comprises a third domain that comprises a domain that binds to CD19 or CD123, or a third domain that comprises a T cell engager that binds to CD3.

16. The method of claim 1 , wherein the multispecific molecule further comprises a third domain that comprises a tumor-targeting domain that binds to a cancer antigen.

17. The method of claim 1 , wherein the multispecific molecule comprises a mutation that decreases Fc receptor binding to the multispecific molecule relative to a multispecific molecule without the mutation.

18. The method of claim 17 , wherein the multispecific molecule comprises a sequence with at least 95% sequence identity to SEQ ID NO: 42.

19. The method of claim 17 , wherein the mutation that decreases Fc receptor binding is an N297A mutation according to EU Numbering in a constant region or corresponds to the alanine at amino acid 180 of SEQ ID NO: 42.

20. The method of claim 1 , wherein the cancer is a hematological cancer, a solid tumor, or a metastatic cancer.

21. The method of claim 20 , wherein the cancer is:

(i) the solid tumor, wherein the solid tumor is pancreatic cancer, breast cancer, colorectal cancer, lung cancer, skin cancer, ovarian cancer, or liver cancer; or

(ii) the hematological cancer, wherein the hematological cancer is a B-cell malignancy or a T cell malignancy.

22. The method of claim 21 , wherein the cancer is the hematological cancer, and the B-cell malignancy or the T cell malignancy is Hodgkin's lymphoma, Non-Hodgkin's lymphoma, acute myeloid leukemia (AML), chronic myeloid leukemia, myelodysplastic syndrome, multiple myeloma, or acute lymphocytic leukemia.

23. The method of claim 22 , wherein the cancer is the hematological cancer, and the B-cell malignancy is Non-Hodgkin's lymphoma, and wherein the Non-Hodgkin's lymphoma is B cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, mantle cell lymphoma, marginal zone B-cell lymphoma, Burkitt lymphoma, lymphoplasmacytic lymphoma, or hairy cell leukemia.

24. The method of claim 1 , wherein the cytokine molecule is selected from the group consisting of interleukin-2 (IL-2) or a functional fragment or variant thereof, interleukin-7 (IL-7) or a functional fragment or variant thereof, interleukin-12 (IL-12) or a functional fragment or variant thereof, interleukin-15 (IL-15) or a functional fragment or variant thereof, interleukin-18 (IL-18) or a functional fragment or variant thereof, interleukin-21 (IL-21) or a functional fragment or variant thereof, and interferon gamma or a functional fragment or variant thereof.

25. The method of claim 1 , wherein the cytokine molecule comprises a sequence with at least 95% sequence identity to SEQ ID NO: 2170, SEQ ID NO: 2180, SEQ ID NO: 2191, SEQ ID NO: 2270, SEQ ID NO: 2280, or SEQ ID NO: 2320.

26. The method of claim 1 , wherein the second domain binds to a second target molecule expressed by the same T cell expressing the TCRβV to which the first domain of the multispecific molecule binds.

27. The method of claim 26 , wherein binding of the first domain to the TCRβV and binding of the second domain to the second target molecule promotes the T cell to kill cancer cells.

28. The method of claim 1 , wherein

the VH and the VL comprise the sequence the sequences of:

(i) SEQ ID NO: 1 and SEQ ID NO: 2, respectively;

(ii) SEQ ID NO: 9 and SEQ ID NO: 10; respectively;

(iii) SEQ ID NO: 9 and SEQ ID NO: 11; respectively;

(iv) SEQ ID NO: 82 and SEQ ID NO: 81, respectively;

(v) SEQ ID NO: 85 and SEQ ID NO: 84, respectively;

(vi) SEQ ID NO: 88 and SEQ ID NO: 87, respectively;

(vii) SEQ ID NO: 91 and SEQ ID NO: 90, respectively;

(viii) SEQ ID NO: 94 and SEQ ID NO: 93, respectively;

(ix) SEQ ID NO: 97 and SEQ ID NO: 96, respectively;

(x) SEQ ID NO: 100 and SEQ ID NO: 99, respectively;

(xi) SEQ ID NO: 103 and SEQ ID NO: 102, respectively;

(xii) SEQ ID NO: 106 and SEQ ID NO: 105, respectively;

(xiii) SEQ ID NO: 109 and SEQ ID NO: 108, respectively;

(xiv) SEQ ID NO: 112 and SEQ ID NO: 111, respectively;

(xv) SEQ ID NO: 115 and SEQ ID NO: 114, respectively;

(xvi) SEQ ID NO: 118 and SEQ ID NO: 117, respectively;

(xvii) SEQ ID NO: 121 and SEQ ID NO: 120, respectively;

(xviii) SEQ ID NO: 124 and SEQ ID NO: 123, respectively;

(xix) SEQ ID NO: 127 and SEQ ID NO: 126, respectively;

(xx) SEQ ID NO: 130 and SEQ ID NO: 129, respectively;

(xxi) SEQ ID NO: 133 and SEQ ID NO: 132, respectively;

(xxii) SEQ ID NO: 136 and SEQ ID NO: 135, respectively;

(xxiii) SEQ ID NO: 139 and SEQ ID NO: 138, respectively;

(xxiv) SEQ ID NO: 142 and SEQ ID NO: 141, respectively;

(xxv) SEQ ID NO: 145 and SEQ ID NO: 144, respectively;

(xxvi) SEQ ID NO: 148 and SEQ ID NO: 147, respectively;

(xxvii) SEQ ID NO: 151 and SEQ ID NO: 150, respectively;

(xxviii) SEQ ID NO: 155 and SEQ ID NO: 154, respectively;

(xxix) SEQ ID NO: 158 and SEQ ID NO: 157, respectively;

(xxx) SEQ ID NO: 161 and SEQ ID NO: 160, respectively;

(xxxi) SEQ ID NO: 164 and SEQ ID NO: 163, respectively;

(xxxii) SEQ ID NO: 167 and SEQ ID NO: 166, respectively;

(xxxiii) SEQ ID NO: 170 and SEQ ID NO: 169, respectively;

(xxxiv) SEQ ID NO: 173 and SEQ ID NO: 172, respectively;

(xxxv) SEQ ID NO: 176 and SEQ ID NO: 175, respectively;

(xxxvi) SEQ ID NO: 179 and SEQ ID NO: 178, respectively;

(xxxvii) SEQ ID NO: 182 and SEQ ID NO: 181, respectively;

(xxxviii) SEQ ID NO: 185 and SEQ ID NO: 184, respectively;

(xxxix) SEQ ID NO: 188 and SEQ ID NO: 187, respectively;

(xl) SEQ ID NO: 191 and SEQ ID NO: 190, respectively;

(xli) SEQ ID NO: 194 and SEQ ID NO: 193, respectively;

(xlii) SEQ ID NO: 197 and SEQ ID NO: 196, respectively;

(xliii) SEQ ID NO: 200 and SEQ ID NO: 199, respectively;

(xliv) SEQ ID NO: 203 and SEQ ID NO: 202, respectively;

(xlv) SEQ ID NO: 205 and amino acids 140-246 of SEQ ID NO: 204, respectively;

(xlvi) SEQ ID NO: 207 and SEQ ID NO: 10, respectively;

(xlvii) SEQ ID NO: 209 and SEQ ID NO: 10, respectively;

(xlviii) SEQ ID NO: 211 and SEQ ID NO: 10, respectively;

(xlix) SEQ ID NO: 213 and SEQ ID NO: 10, respectively;

(l) SEQ ID NO: 215 and SEQ ID NO: 10, respectively;

(li) SEQ ID NO: 217 and SEQ ID NO: 10, respectively;

(lii) SEQ ID NO: 219 and SEQ ID NO: 10, respectively;

(lii) SEQ ID NO: 221 and SEQ ID NO: 10, respectively;

(liv) SEQ ID NO: 223 and SEQ ID NO: 10, respectively; or

(lv) SEQ ID NO: 225 and SEQ ID NO: 10, respectively.

29. The method of claim 1 , wherein the first domain comprises a sequence having at least 90% sequence identity to any one sequence selected from the group consisting of SEQ ID NOs: 80, 83, 86, 89, 92, 95, 98, 101, 104, 107, 110, 113, 116, 119, 122, 125, 128, 131, 134, 137, 140, 143, 146, 149, 153, 156, 159, 162, 165, 168, 171, 174, 177, 180, 183, 186, 189, 192, 195, 198, 201, 204, 206, 208, 210, 212, 214, 216, 218, 220, 222, and 224.

Assignments (2)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2022

From: TAN, SENG-LAI; VASH, BRIAN EDWARD; HSU, JONATHAN; GUNASEKERA, DILINI CHARMAIN; PALAKURTHI, SANGEETHA SAGAR; LOEW, ANDREAS

To: ELSTAR THERAPEUTICS, INC.

Reel/Frame 061283/0084 →

CHANGE OF NAME Recorded Aug 19, 2022

From: ELSTAR THERAPEUTICS, INC.

To: MARENGO THERAPEUTICS, INC.

Reel/Frame 061283/0526 →

Continuity (6)

Continuation 17256917

Provisional Application 62808700 · Feb 21, 2019

Provisional Application 62788674 · Jan 4, 2019

Provisional Application 62737829 · Sep 27, 2018

Provisional Application 62693653 · Jul 3, 2018

Related Publication 20230174650A1 · Jun 8, 2023

References Cited (400)

US 861745A · Maxwell · 1907 [cited by applicant]

US 4433059A · Chang et al. · 1984 [cited by applicant]

US 4439196A · Higuchi · 1984 [cited by applicant]

US 4444878A · Paulus · 1984 [cited by applicant]

US 4447224A · DeCant, Jr. et al. · 1984 [cited by applicant]

US 4447233A · Mayfield · 1984 [cited by applicant]

US 4475196A · La Zor · 1984 [cited by applicant]

US 4486194A · Ferrara · 1984 [cited by applicant]

US 4487603A · Harris · 1984 [cited by applicant]

US 4522811A · Eppstein et al. · 1985 [cited by applicant]

US 4596556A · Morrow et al. · 1986 [cited by applicant]

US 4676980A · Segal et al. · 1987 [cited by applicant]

US 4737456A · Weng et al. · 1988 [cited by applicant]

US 4790824A · Morrow et al. · 1988 [cited by applicant]

US 4816567A · Cabilly et al. · 1989 [cited by applicant]

US 4941880A · Burns · 1990 [cited by applicant]

US 5057423A · Hiserodt et al. · 1991 [cited by applicant]

US 5064413A · McKinnon et al. · 1991 [cited by applicant]

US 5116615A · Gokcen et al. · 1992 [cited by applicant]

US 5208020A · Chari et al. · 1993 [cited by applicant]

US 5223409A · Ladner et al. · 1993 [cited by applicant]

US 5225539A · Winter · 1993 [cited by applicant]

US 5273743A · Ahlem et al. · 1993 [cited by applicant]

US 5312335A · Mckinnon et al. · 1994 [cited by applicant]

US 5374548A · Caras · 1994 [cited by applicant]

US 5383851A · McKinnon, Jr. et al. · 1995 [cited by applicant]

US 5391377A · Barnwell · 1995 [cited by applicant]

US 5399163A · Peterson et al. · 1995 [cited by applicant]

US 5399331A · Loughrey et al. · 1995 [cited by applicant]

US 5416016A · Low et al. · 1995 [cited by applicant]

US 5416064A · Chari et al. · 1995 [cited by applicant]

US 5500362A · Robinson et al. · 1996 [cited by applicant]

US 5534254A · Huston et al. · 1996 [cited by applicant]

US 5571894A · Wels et al. · 1996 [cited by applicant]

US 5582996A · Curtis · 1996 [cited by applicant]

US 5585089A · Queen et al. · 1996 [cited by applicant]

US 5587458A · King et al. · 1996 [cited by applicant]

US 5591828A · Bosslet et al. · 1997 [cited by applicant]

US 5624821A · Winter et al. · 1997 [cited by applicant]

US 5626561A · Butler et al. · 1997 [cited by applicant]

US 5635483A · Pettit et al. · 1997 [cited by applicant]

US 5635602A · Cantor et al. · 1997 [cited by applicant]

US 5637481A · Ledbetter et al. · 1997 [cited by applicant]

US 5641870A · Rinderknecht et al. · 1997 [cited by applicant]

US 5648237A · Carter · 1997 [cited by applicant]

US 5648260A · Winter et al. · 1997 [cited by applicant]

US 5693761A · Queen et al. · 1997 [cited by applicant]

US 5693762A · Queen et al. · 1997 [cited by applicant]

US 5712374A · Kuntsmann et al. · 1998 [cited by applicant]

US 5714586A · Kunstmann et al. · 1998 [cited by applicant]

US 5731116A · Matsuo et al. · 1998 [cited by applicant]

US 5731168A · Carter et al. · 1998 [cited by applicant]

US 5739116A · Hamann et al. · 1998 [cited by applicant]

US 5747036A · Brenner et al. · 1998 [cited by applicant]

US 5750373A · Garrard et al. · 1998 [cited by applicant]

US 5766947A · Rittershaus et al. · 1998 [cited by applicant]

US 5767285A · Hamann et al. · 1998 [cited by applicant]

US 5770429A · Lonberg et al. · 1998 [cited by applicant]

US 5770701A · McGahren et al. · 1998 [cited by applicant]

US 5770710A · McGahren et al. · 1998 [cited by applicant]

US 5773001A · Hamann et al. · 1998 [cited by applicant]

US 5780588A · Pettit et al. · 1998 [cited by applicant]

US 5787900A · Butler et al. · 1998 [cited by applicant]

US 5789199A · Joly et al. · 1998 [cited by applicant]

US 5811097A · Allison et al. · 1998 [cited by applicant]

US 5821337A · Carter et al. · 1998 [cited by applicant]

US 5831012A · Nilsson et al. · 1998 [cited by applicant]

US 5837242A · Holliger et al. · 1998 [cited by applicant]

US 5837821A · Wu · 1998 [cited by applicant]

US 5840523A · Simmons et al. · 1998 [cited by applicant]

US 5843069A · Butler et al. · 1998 [cited by applicant]

US 5844094A · Hudson et al. · 1998 [cited by applicant]

US 5849500A · Breitling et al. · 1998 [cited by applicant]

US 5849589A · Tedder et al. · 1998 [cited by applicant]

US 5861155A · Lin · 1999 [cited by applicant]

US 5864019A · King et al. · 1999 [cited by applicant]

US 5869046A · Presta et al. · 1999 [cited by applicant]

US 5869620A · Whitlow et al. · 1999 [cited by applicant]

US 5877296A · Hamann et al. · 1999 [cited by applicant]

US 5902745A · Butler et al. · 1999 [cited by applicant]

US 5910573A · Plueckthun et al. · 1999 [cited by applicant]

US 5913998A · Butler et al. · 1999 [cited by applicant]

US 5932448A · Tso et al. · 1999 [cited by applicant]

US 5959083A · Bosslet et al. · 1999 [cited by applicant]

US 5959177A · Hein et al. · 1999 [cited by applicant]

US 5968753A · Tseng-Law et al. · 1999 [cited by applicant]

US 5980889A · Butler et al. · 1999 [cited by applicant]

US 5989830A · Davis et al. · 1999 [cited by applicant]

US 6005079A · Casterman et al. · 1999 [cited by applicant]

US 6040498A · Stomp et al. · 2000 [cited by applicant]

US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]

US 6120766A · Hale et al. · 2000 [cited by applicant]

US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]

US 6171586B1 · Lam et al. · 2001 [cited by applicant]

US 6172197B1 · McCafferty et al. · 2001 [cited by applicant]

US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]

US 6239259B1 · Davis et al. · 2001 [cited by applicant]

US 6248516B1 · Winter et al. · 2001 [cited by applicant]

US 6267958B1 · Andya et al. · 2001 [cited by applicant]

US 6291158B1 · Winter et al. · 2001 [cited by applicant]

US 6294353B1 · Pack et al. · 2001 [cited by applicant]

US 6333396B1 · Filpula et al. · 2001 [cited by applicant]

US 6352694B1 · June et al. · 2002 [cited by applicant]

US 6417429B1 · Hein et al. · 2002 [cited by applicant]

US 6420548B1 · Vezina et al. · 2002 [cited by applicant]

US 6476198B1 · Kang · 2002 [cited by applicant]

US 6511663B1 · King et al. · 2003 [cited by applicant]

US 6534055B1 · June et al. · 2003 [cited by applicant]

US 6582915B1 · Griffiths et al. · 2003 [cited by applicant]

US 6593081B1 · Griffiths et al. · 2003 [cited by applicant]

US 6602684B1 · Umana et al. · 2003 [cited by applicant]

US 6630579B2 · Chari et al. · 2003 [cited by applicant]

US 6632427B1 · Finiels et al. · 2003 [cited by applicant]

US 6670453B2 · Frenken et al. · 2003 [cited by applicant]

US 6696245B2 · Winter et al. · 2004 [cited by applicant]

US 6703199B1 · Koide · 2004 [cited by applicant]

US 6737056B1 · Presta · 2004 [cited by applicant]

US 6743896B2 · Filpula et al. · 2004 [cited by applicant]

US 6756523B1 · Kahn et al. · 2004 [cited by applicant]

US 6765087B1 · Casterman et al. · 2004 [cited by applicant]

US 6809185B1 · Schoonjans et al. · 2004 [cited by applicant]

US 6818418B1 · Lipovsek et al. · 2004 [cited by applicant]

US 6833441B2 · Wang et al. · 2004 [cited by applicant]

US 6838254B1 · Hamers et al. · 2005 [cited by applicant]

US 6905680B2 · June et al. · 2005 [cited by applicant]

US 6979546B2 · Moretta et al. · 2005 [cited by applicant]

US 6982321B2 · Winter · 2006 [cited by applicant]

US 7041870B2 · Tomizuka et al. · 2006 [cited by applicant]

US 7083785B2 · Browning et al. · 2006 [cited by applicant]

US 7087409B2 · Barbas, III et al. · 2006 [cited by applicant]

US 7105149B1 · Dalla-Favera · 2006 [cited by applicant]

US 7125978B1 · Vezina et al. · 2006 [cited by applicant]

US 7129330B1 · Little et al. · 2006 [cited by applicant]

US 7183076B2 · Arathoon et al. · 2007 [cited by applicant]

US 7186804B2 · Gillies et al. · 2007 [cited by applicant]

US 7189826B2 · Rodman · 2007 [cited by applicant]

US 7250297B1 · Beste et al. · 2007 [cited by applicant]

US 7276241B2 · Schneider et al. · 2007 [cited by applicant]

US 7332581B2 · Presta · 2008 [cited by applicant]

US 7361360B2 · Kitabwalla et al. · 2008 [cited by applicant]

US 7371826B2 · Presta · 2008 [cited by applicant]

US 7402314B2 · Sherman · 2008 [cited by applicant]

US 7431380B1 · Buresh · 2008 [cited by applicant]

US 7476724B2 · Dennis et al. · 2009 [cited by applicant]

US 7498298B2 · Doronina et al. · 2009 [cited by applicant]

US 7501121B2 · Tchistiakova et al. · 2009 [cited by applicant]

US 7517966B2 · Moretta et al. · 2009 [cited by applicant]

US 7521056B2 · Chang et al. · 2009 [cited by applicant]

US 7521541B2 · Eigenbrot et al. · 2009 [cited by applicant]

US 7527787B2 · Chang et al. · 2009 [cited by applicant]

US 7527791B2 · Adams et al. · 2009 [cited by applicant]

US 7534866B2 · Chang et al. · 2009 [cited by applicant]

US 7563441B2 · Graus et al. · 2009 [cited by applicant]

US 7601803B1 · Fiedler et al. · 2009 [cited by applicant]

US 7612181B2 · Wu et al. · 2009 [cited by applicant]

US 7642228B2 · Carter et al. · 2010 [cited by applicant]

US 7700739B2 · Lacy et al. · 2010 [cited by applicant]

US 7741446B2 · Pardridge et al. · 2010 [cited by applicant]

US 7750128B2 · Gegg et al. · 2010 [cited by applicant]

US 7767429B2 · Bookbinder et al. · 2010 [cited by applicant]

US 7799902B2 · Browning et al. · 2010 [cited by applicant]

US 7803376B2 · Velardi et al. · 2010 [cited by applicant]

US 7807160B2 · Presta et al. · 2010 [cited by applicant]

US 7829289B2 · Lantz et al. · 2010 [cited by applicant]

US 7855275B2 · Eigenbrot et al. · 2010 [cited by applicant]

US 7858759B2 · Brandt et al. · 2010 [cited by applicant]

US 7906118B2 · Chang et al. · 2011 [cited by applicant]

US 7919257B2 · Hoogenboom et al. · 2011 [cited by applicant]

US 7943743B2 · Korman et al. · 2011 [cited by applicant]

US 7999077B2 · Pastan et al. · 2011 [cited by applicant]

US 8003774B2 · Stavenhagen et al. · 2011 [cited by applicant]

US 8008449B2 · Korman et al. · 2011 [cited by applicant]

US 8012465B2 · Elias et al. · 2011 [cited by applicant]

US 8034326B2 · Hjorth et al. · 2011 [cited by applicant]

US 8202517B2 · Bookbinder et al. · 2012 [cited by applicant]

US 8216805B2 · Carter et al. · 2012 [cited by applicant]

US 8227577B2 · Klein et al. · 2012 [cited by applicant]

US 8299220B2 · Dalla-Favera · 2012 [cited by applicant]

US 8354509B2 · Carven et al. · 2013 [cited by applicant]

US 8362213B2 · Elkins et al. · 2013 [cited by applicant]

US 8450470B2 · Bookbinder et al. · 2013 [cited by applicant]

US 8466260B2 · Elkins et al. · 2013 [cited by applicant]

US 8552156B2 · Takayanagi et al. · 2013 [cited by applicant]

US 8580252B2 · Bookbinder et al. · 2013 [cited by applicant]

US 8586713B2 · Davis et al. · 2013 [cited by applicant]

US 8592562B2 · Kannan et al. · 2013 [cited by applicant]

US 8609089B2 · Langermann et al. · 2013 [cited by applicant]

US 8617545B2 · Hsu et al. · 2013 [cited by applicant]

US 8617559B2 · Elkins et al. · 2013 [cited by applicant]

US 8658135B2 · O'Connor-McCourt et al. · 2014 [cited by applicant]

US 8703132B2 · Imhof-Jung et al. · 2014 [cited by applicant]

US 8772246B2 · Bookbinder et al. · 2014 [cited by applicant]

US 8790895B2 · Fiedler et al. · 2014 [cited by applicant]

US 8821883B2 · Ambrose et al. · 2014 [cited by applicant]

US 8846042B2 · Zhou · 2014 [cited by applicant]

US 8871912B2 · Davis et al. · 2014 [cited by applicant]

US 8920776B2 · Gaiger et al. · 2014 [cited by applicant]

US 8945571B2 · Mossner et al. · 2015 [cited by applicant]

US 8993524B2 · Bedi et al. · 2015 [cited by applicant]

US 9000130B2 · Bhakta et al. · 2015 [cited by applicant]

US 9034324B2 · Kalled et al. · 2015 [cited by applicant]

US 9056905B2 · Olson et al. · 2015 [cited by applicant]

US 9145588B2 · Throsby et al. · 2015 [cited by applicant]

US 9200060B2 · Kannan et al. · 2015 [cited by applicant]

US 9243058B2 · Armitage et al. · 2016 [cited by applicant]

US 9309311B2 · Gurney et al. · 2016 [cited by applicant]

US 9340621B2 · Kufer et al. · 2016 [cited by applicant]

US 9358286B2 · De et al. · 2016 [cited by applicant]

US 9359437B2 · Davis et al. · 2016 [cited by applicant]

US 9382323B2 · Brinkmann et al. · 2016 [cited by applicant]

US 9387237B2 · Kalled et al. · 2016 [cited by applicant]

US 9416187B2 · Tedder et al. · 2016 [cited by applicant]

US 9447159B2 · Ast et al. · 2016 [cited by applicant]

US 9447185B2 · Romagne et al. · 2016 [cited by applicant]

US 9545086B2 · Mackay et al. · 2017 [cited by applicant]

US 9593376B2 · Zitvogel et al. · 2017 [cited by applicant]

US 9663577B2 · Pierres et al. · 2017 [cited by applicant]

US 9676863B2 · Lo · 2017 [cited by applicant]

US 9833476B2 · Zhang et al. · 2017 [cited by applicant]

US 10150816B2 · Abbot et al. · 2018 [cited by applicant]

US 10294300B2 · Raum et al. · 2019 [cited by applicant]

US 10308721B2 · Williams et al. · 2019 [cited by applicant]

US 10478509B2 · Torgov et al. · 2019 [cited by applicant]

US 10610571B2 · Ptacin et al. · 2020 [cited by applicant]

US 10676516B2 · Viney et al. · 2020 [cited by applicant]

US 10730942B2 · Pule et al. · 2020 [cited by applicant]

US 10815311B2 · Wesche et al. · 2020 [cited by applicant]

US 11033634B2 · Stull et al. · 2021 [cited by applicant]

US 11291721B2 · Loew et al. · 2022 [cited by applicant]

US 11292838B2 · Schendel et al. · 2022 [cited by applicant]

US 11673953B2 · Zhang et al. · 2023 [cited by applicant]

US 11692031B2 · Dahlhoff et al. · 2023 [cited by applicant]

US 11845797B2 · Tan et al. · 2023 [cited by applicant]

US 11965025B2 · Tan · 2024 [cited by examiner]

US 20020004587A1 · Miller et al. · 2002 [cited by applicant]

US 20020041865A1 · Austin et al. · 2002 [cited by applicant]

US 20020062010A1 · Arathoon et al. · 2002 [cited by applicant]

US 20020076406A1 · Leung · 2002 [cited by applicant]

US 20020103345A1 · Zhu · 2002 [cited by applicant]

US 20020115214A1 · June et al. · 2002 [cited by applicant]

US 20020164328A1 · Shinkawa et al. · 2002 [cited by applicant]

US 20030115614A1 · Kanda et al. · 2003 [cited by applicant]

US 20030130496A1 · Winter et al. · 2003 [cited by applicant]

US 20030157108A1 · Presta · 2003 [cited by applicant]

US 20030175884A1 · Umana et al. · 2003 [cited by applicant]

US 20030207346A1 · Arathoon et al. · 2003 [cited by applicant]

US 20030211078A1 · Heavner · 2003 [cited by applicant]

US 20040009530A1 · Wilson et al. · 2004 [cited by applicant]

US 20040093621A1 · Shitara et al. · 2004 [cited by applicant]

US 20040109865A1 · Niwa et al. · 2004 [cited by applicant]

US 20040110282A1 · Kanda et al. · 2004 [cited by applicant]

US 20040110704A1 · Yamane et al. · 2004 [cited by applicant]

US 20040132140A1 · Satoh et al. · 2004 [cited by applicant]

US 20040175756A1 · Kolkman et al. · 2004 [cited by applicant]

US 20040219643A1 · Winter et al. · 2004 [cited by applicant]

US 20040220388A1 · Mertens et al. · 2004 [cited by applicant]

US 20040241817A1 · Umana et al. · 2004 [cited by applicant]

US 20040242847A1 · Fukushima et al. · 2004 [cited by applicant]

US 20050003403A1 · Rossi et al. · 2005 [cited by applicant]

US 20050004352A1 · Kontermann et al. · 2005 [cited by applicant]

US 20050014934A1 · Hinton et al. · 2005 [cited by applicant]

US 20050048512A1 · Kolkman et al. · 2005 [cited by applicant]

US 20050053973A1 · Kolkman et al. · 2005 [cited by applicant]

US 20050069552A1 · Bleck et al. · 2005 [cited by applicant]

US 20050079170A1 · Le Gall et al. · 2005 [cited by applicant]

US 20050079574A1 · Bond · 2005 [cited by applicant]

US 20050090648A1 · Tsurushita et al. · 2005 [cited by applicant]

US 20050100543A1 · Hansen et al. · 2005 [cited by applicant]

US 20050119455A1 · Fuh et al. · 2005 [cited by applicant]

US 20050123546A1 · Umana et al. · 2005 [cited by applicant]

US 20050136049A1 · Ledbetter et al. · 2005 [cited by applicant]

US 20050136051A1 · Scallon · 2005 [cited by applicant]

US 20050163782A1 · Glaser et al. · 2005 [cited by applicant]

US 20050260186A1 · Bookbinder et al. · 2005 [cited by applicant]

US 20050266000A1 · Bond et al. · 2005 [cited by applicant]

US 20050266425A1 · Zauderer et al. · 2005 [cited by applicant]

US 20060008844A1 · Stemmer et al. · 2006 [cited by applicant]

US 20060025576A1 · Miller et al. · 2006 [cited by applicant]

US 20060083747A1 · Winter et al. · 2006 [cited by applicant]

US 20060104968A1 · Bookbinder et al. · 2006 [cited by applicant]

US 20060120960A1 · Deyev et al. · 2006 [cited by applicant]

US 20060141581A1 · Gillies et al. · 2006 [cited by applicant]

US 20060204493A1 · Huang et al. · 2006 [cited by applicant]

US 20060263367A1 · Fey et al. · 2006 [cited by applicant]

US 20070004909A1 · Johnson et al. · 2007 [cited by applicant]

US 20070036783A1 · Humeau et al. · 2007 [cited by applicant]

US 20070061900A1 · Murphy et al. · 2007 [cited by applicant]

US 20070087381A1 · Kojima · 2007 [cited by applicant]

US 20070105105A1 · Clelland et al. · 2007 [cited by applicant]

US 20070117126A1 · Sidhu et al. · 2007 [cited by applicant]

US 20070128150A1 · Norman · 2007 [cited by applicant]

US 20070141049A1 · Bredehorst et al. · 2007 [cited by applicant]

US 20070154901A1 · Thogersen et al. · 2007 [cited by applicant]

US 20070160598A1 · Dennis et al. · 2007 [cited by applicant]

US 20070178106A1 · Romagne · 2007 [cited by applicant]

US 20070184052A1 · Lin et al. · 2007 [cited by applicant]

US 20070231322A1 · Romagne et al. · 2007 [cited by applicant]

US 20070237764A1 · Birtalan et al. · 2007 [cited by applicant]

US 20070274985A1 · Dubel et al. · 2007 [cited by applicant]

US 20070292936A1 · Barthelemy et al. · 2007 [cited by applicant]

US 20080050370A1 · Glaser et al. · 2008 [cited by applicant]

US 20080063717A1 · Romagne et al. · 2008 [cited by applicant]

US 20080069820A1 · Fuh et al. · 2008 [cited by applicant]

US 20080152645A1 · Pardridge et al. · 2008 [cited by applicant]

US 20080171855A1 · Rossi et al. · 2008 [cited by applicant]

US 20080241884A1 · Shitara et al. · 2008 [cited by applicant]

US 20080247944A1 · Graziano et al. · 2008 [cited by applicant]

US 20080254512A1 · Capon · 2008 [cited by applicant]

US 20080260738A1 · Moore et al. · 2008 [cited by applicant]

US 20080299137A1 · Svendsen et al. · 2008 [cited by applicant]

US 20090002360A1 · Chen et al. · 2009 [cited by applicant]

US 20090010843A1 · Spee et al. · 2009 [cited by applicant]

US 20090130106A1 · Christopherson et al. · 2009 [cited by applicant]

US 20090148905A1 · Ashman et al. · 2009 [cited by applicant]

US 20090155275A1 · Wu et al. · 2009 [cited by applicant]

US 20090162359A1 · Klein et al. · 2009 [cited by applicant]

US 20090162360A1 · Klein et al. · 2009 [cited by applicant]

US 20090175851A1 · Klein et al. · 2009 [cited by applicant]

US 20090175867A1 · Thompson et al. · 2009 [cited by applicant]

US 20090214533A1 · Clynes · 2009 [cited by applicant]

US 20090232811A1 · Klein et al. · 2009 [cited by applicant]

US 20090234105A1 · Gervay-Hague et al. · 2009 [cited by applicant]

US 20090263392A1 · Igawa et al. · 2009 [cited by applicant]

US 20090274649A1 · Qu et al. · 2009 [cited by applicant]

US 20090280116A1 · Smith et al. · 2009 [cited by applicant]

US 20090324538A1 · Wong et al. · 2009 [cited by applicant]

US 20100015133A1 · Igawa et al. · 2010 [cited by applicant]

US 20100028330A1 · Collins et al. · 2010 [cited by applicant]

US 20100047169A1 · Mandelboim et al. · 2010 [cited by applicant]

US 20100168393A1 · Clube et al. · 2010 [cited by applicant]

US 20100260704A1 · Berenguer et al. · 2010 [cited by applicant]

US 20100316645A1 · Imhof-Jung et al. · 2010 [cited by applicant]

US 20110014659A1 · Balazs et al. · 2011 [cited by applicant]

US 20110054151A1 · Lazar et al. · 2011 [cited by applicant]

US 20110091372A1 · Ghayur et al. · 2011 [cited by applicant]

US 20110150892A1 · Thudium et al. · 2011 [cited by applicant]

US 20110177073A1 · Van Berkel et al. · 2011 [cited by applicant]

US 20110177093A1 · Kalled et al. · 2011 [cited by applicant]

US 20110250170A1 · Pedretti et al. · 2011 [cited by applicant]

US 20110287056A1 · Gu et al. · 2011 [cited by applicant]

US 20110293613A1 · Brinkmann et al. · 2011 [cited by applicant]

US 20120034221A1 · Bonvini et al. · 2012 [cited by applicant]

US 20120039906A1 · Olive · 2012 [cited by applicant]

US 20120114649A1 · Langermann et al. · 2012 [cited by applicant]

US 20120149876A1 · Von Kreudenstein et al. · 2012 [cited by applicant]

US 20120184716A1 · Fischer et al. · 2012 [cited by applicant]

US 20120201746A1 · Liu et al. · 2012 [cited by applicant]

US 20120213768A1 · Oh et al. · 2012 [cited by applicant]

US 20120294857A1 · Sentman et al. · 2012 [cited by applicant]

US 20130017200A1 · Scheer et al. · 2013 [cited by applicant]

US 20130022601A1 · Brinkmann et al. · 2013 [cited by applicant]

US 20130078249A1 · Ast et al. · 2013 [cited by applicant]

US 20130129723A1 · Blankenship · 2013 [cited by examiner]

US 20130165638A1 · Hsu et al. · 2013 [cited by applicant]

US 20130178605A1 · Blein et al. · 2013 [cited by applicant]

US 20130195849A1 · Spreter Von Kreudenstein et al. · 2013 [cited by applicant]

US 20130243775A1 · Papadopoulos et al. · 2013 [cited by applicant]

US 20130266568A1 · Brinkmann et al. · 2013 [cited by applicant]

US 20130267686A1 · Brinkmann et al. · 2013 [cited by applicant]

US 20130273055A1 · Borges et al. · 2013 [cited by applicant]

US 20130273089A1 · Getts et al. · 2013 [cited by applicant]

US 20130280208A1 · Stepkowski et al. · 2013 [cited by applicant]

US 20130303396A1 · Igawa et al. · 2013 [cited by applicant]

US 20130317200A1 · Elson et al. · 2013 [cited by applicant]

US 20140037621A1 · Tsurushita et al. · 2014 [cited by applicant]

US 20140044728A1 · Takayanagi et al. · 2014 [cited by applicant]

US 20140051833A1 · Fischer et al. · 2014 [cited by applicant]

US 20140051835A1 · Dixit et al. · 2014 [cited by applicant]

US 20140072528A1 · Gerdes et al. · 2014 [cited by applicant]

US 20140072581A1 · Dixit et al. · 2014 [cited by applicant]

US 20140079689A1 · Elliott et al. · 2014 [cited by applicant]

US 20140079691A1 · McConnell et al. · 2014 [cited by applicant]

US 20140099254A1 · Chang et al. · 2014 [cited by applicant]

US 20140154254A1 · Kannan et al. · 2014 [cited by applicant]

US 20140199294A1 · Mimoto et al. · 2014 [cited by applicant]

US 20140200331A1 · Corper et al. · 2014 [cited by applicant]

US 20140227265A1 · Wu et al. · 2014 [cited by applicant]

US 20140242075A1 · Parren et al. · 2014 [cited by applicant]

US 20140242077A1 · Choi et al. · 2014 [cited by applicant]

US 20140256916A1 · Kruip et al. · 2014 [cited by applicant]

US 20140308285A1 · Yan et al. · 2014 [cited by applicant]

US 20140322212A1 · Brogdon et al. · 2014 [cited by applicant]

US 20140322221A1 · Miller et al. · 2014 [cited by applicant]

US 20140348839A1 · Chowdhury et al. · 2014 [cited by applicant]

US 20140363426A1 · Moore et al. · 2014 [cited by applicant]

US 20140377269A1 · Mabry et al. · 2014 [cited by applicant]

US 20150017187A1 · Thanos et al. · 2015 [cited by applicant]

US 20150018529A1 · Humphreys et al. · 2015 [cited by applicant]

US 20150056199A1 · Kumar et al. · 2015 [cited by applicant]

US 20150098900A1 · Ebens et al. · 2015 [cited by applicant]

US 20150133638A1 · Wranik et al. · 2015 [cited by applicant]

US 20150166661A1 · Chen et al. · 2015 [cited by applicant]

US 20150166670A1 · Castoldi et al. · 2015 [cited by applicant]

US 20150175707A1 · De Jong et al. · 2015 [cited by applicant]

US 20150203591A1 · Yancopoulos et al. · 2015 [cited by applicant]

US 20150211001A1 · Ohrn et al. · 2015 [cited by applicant]

US 20150218260A1 · Klein et al. · 2015 [cited by applicant]

US 20150232560A1 · Heindl et al. · 2015 [cited by applicant]

US 20150315296A1 · Schaefer et al. · 2015 [cited by applicant]

US 20150337049A1 · Labrijn et al. · 2015 [cited by applicant]

Cited By (1)

US 12,486,326